Clinical Documentation Guide: COVID-19 and Post-COVID Conditions

🔍 Section 1 — Definition

COVID-19 (Coronavirus Disease 2019) is an infectious illness caused by the SARS-CoV-2 virus, first identified in late 2019. The disease ranges from asymptomatic infection to critical illness with multi-organ failure. For ICD-10-CM reporting purposes, code U07.1, COVID-19, is the primary classification under Chapter 22 (Codes for Special Purposes, U00–U85), per CMS FY2026 ICD-10-CM Official Guidelines for Coding and Reporting.

Post-COVID-19 Condition (also called Long COVID or PASC — Post-Acute Sequelae of SARS-CoV-2 Infection) refers to a wide range of new, returning, or ongoing health problems that people experience four or more weeks after first being infected with SARS-CoV-2. These conditions persist after the acute phase of infection has resolved. ICD-10-CM code U09.9, Post COVID-19 condition, unspecified, was effective October 1, 2021, and remains the anchor code for post-COVID sequelae, per CDC NCHS announcement.

Multisystem Inflammatory Syndrome (MIS) — including MIS in Children (MIS-C) and MIS in Adults (MIS-A) — is a serious hyperinflammatory condition associated with SARS-CoV-2, coded to M35.81, Multisystem inflammatory syndrome. Coding conventions differ depending on whether the patient has active COVID-19, a history of COVID-19, or only exposure to COVID-19, as detailed in FY2026 Guideline I.C.1.g.1.l.

🗂️ Section 2 — Alternative Terminology

COVID-19 and its sequelae are referred to by numerous clinical, lay, and administrative terms. Coders and CDI specialists must recognize all variants to ensure correct code assignment and complete documentation capture.

🩺 Section 3 — Signs & Symptoms

COVID-19 presents across a broad spectrum. When a definitive diagnosis of COVID-19 has not been established, coders assign the presenting signs and symptoms rather than U07.1, per FY2026 Guideline I.C.1.g.1.g.

Acute COVID-19 — Common Presenting Signs/Symptoms:

• Fever (R50.9), chills (R68.83)
• Cough — acute (R05.1), unspecified (R05.9)
• Shortness of breath / dyspnea (R06.02)
• Fatigue (R53.83)
• Myalgia (M79.3)
• Headache (R51.9)
• Loss of smell / anosmia (R43.0)
• Loss of taste / ageusia (R43.2)
• Sore throat (J02.9)
• Nausea, vomiting, diarrhea (R11.0, R11.10, R19.7)
• Chest pain (R07.9)

Post-COVID-19 (Long COVID) — Persistent/New Symptoms:

• Fatigue / post-exertional malaise (R53.83)
• Brain fog / cognitive impairment (R41.840)
• Dyspnea / breathlessness (R06.02)
• Palpitations (R00.2)
• Persistent anosmia (R43.0) or ageusia (R43.2)
• Post-exertional symptom exacerbation
• Sleep disturbance (G47.00)
• Depression (F32.9), anxiety (F41.9)
• Orthostatic intolerance / POTS (G90.3)
• Chronic respiratory failure (J96.10)

🧭 Section 4 — Differential Diagnosis

COVID-19 shares symptoms with a wide range of respiratory and systemic illnesses. Clinical differentiation relies on testing, clinical context, and provider documentation. Coders should not independently determine whether a patient has COVID-19 vs. an alternative diagnosis.

📋 Section 5 — Clinical Indicators for Coders/CDI

The following clinical indicators help coders and CDI specialists identify opportunities to accurately report COVID-19 and post-COVID conditions. Documentation must support each code assigned.

🦴 Section 6 — Anatomy & Pathophysiology

SARS-CoV-2 is a positive-sense, single-stranded RNA betacoronavirus. It enters human cells primarily via the ACE2 receptor (angiotensin-converting enzyme 2), expressed abundantly in type II pneumocytes, endothelial cells, intestinal epithelium, and cardiac tissue. The spike (S) protein binds ACE2 with assistance from the host serine protease TMPRSS2.

Acute Phase Pathophysiology:

• Pulmonary involvement: Viral replication causes diffuse alveolar damage (DAD), with exudative and proliferative phases. Cytokine storm — marked by elevated IL-6, TNF-α, IL-1β — drives ARDS, endotheliitis, and microvascular thrombosis.
• Cardiovascular: Direct myocardial injury (myocarditis), arrhythmias, and thromboembolic events (PE, DVT) due to hypercoagulability (elevated D-dimer, fibrinogen).
• Neurological: Neuroinvasion via olfactory neurons explains anosmia; encephalopathy may result from hypoxia, cytokine-mediated neuroinflammation, or direct viral invasion.
• Renal: Acute kidney injury (AKI) occurs due to direct tubular injury, hemodynamic compromise, and microvascular thrombosis.

Post-COVID Pathophysiology (PASC):

Research suggests multiple overlapping mechanisms for long COVID, including: (1) viral persistence or reactivation; (2) immune dysregulation with autoantibody formation; (3) microbiome disruption; (4) endothelial dysfunction and microclotting; and (5) reactivation of latent herpesviruses (e.g., EBV). These mechanisms explain the diverse manifestations from fatigue and brain fog to dysautonomia (POTS), mast cell activation, and cardiopulmonary symptoms.

MIS-C / MIS-A Pathophysiology:

MIS is a post-infectious hyperinflammatory syndrome distinct from acute COVID-19. It is hypothesized to involve immune complex deposition, molecular mimicry, and aberrant T-cell activation. MIS-C typically presents 2–6 weeks after acute infection, predominantly in children, with fever, gastrointestinal symptoms, mucocutaneous changes, and cardiac involvement (coronary artery dilation, myocarditis).

💊 Section 7 — Medication Impact / Treatment

Several antiviral and immunomodulatory agents are used in COVID-19 treatment; their use in the medical record should alert coders and CDI specialists to the confirmed or suspected diagnosis.

Antiviral Agents:

• Nirmatrelvir/ritonavir (Paxlovid): FDA-approved oral antiviral for mild-to-moderate COVID-19 in high-risk adults (≥18 years); EUA for adolescents 12–17 years weighing ≥40 kg. Use of Paxlovid in the record strongly indicates a confirmed COVID-19 diagnosis (U07.1). Per 2026 clinical policy guidance, eligible claims must include ICD-10-CM diagnosis code U07.1.
• Remdesivir (Veklury): IV antiviral for hospitalized patients; administered per hospital protocol. Strong indicator of confirmed acute COVID-19.
• Molnupiravir (Lagevrio): Oral antiviral for high-risk adults; not authorized for pediatric patients under 18.

Immunomodulatory / Anti-inflammatory Agents:

• Dexamethasone: Standard of care for hospitalized patients requiring supplemental oxygen or ventilation (RECOVERY trial). Documents disease severity. Presence of corticosteroid therapy should prompt CDI review for severity of illness documentation.
• Baricitinib (Olumiant): JAK inhibitor approved for severe COVID-19 in hospitalized adults.
• Tocilizumab (Actemra): IL-6 receptor antagonist for hospitalized patients with rapid respiratory deterioration; HCPCS code Q0234 (tocilizumab-bavi) effective July 2026 per CMS Transmittal R13733CP.

Vaccination — Coding:

COVID-19 vaccination status should be documented. Vaccine administration is reported with CPT codes 90476–91300 series. Combined COVID-19/influenza mRNA vaccines include CPT 90612 and 90613 (new for CY2026), per AMA CPT COVID-19 vaccine codes.

Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.

← Back to All Clinical Documentation Guides